CancerVax and Micromet merge | Chemical & Engineering News
Volume 84 Issue 3 | p. 16 | Concentrates
Issue Date: January 16, 2006

CancerVax and Micromet merge

Department: Business

CancerVax has agreed to merge with German biopharmaceutical company Micromet. Shareholders of Micromet will own roughly 67.5% of the combined entity, which will be renamed Micromet Inc. CancerVax has struggled to recover after discontinuing development of its lead product, the cancer vaccine Canvaxin, last October. The merger will refuel CancerVax's pipeline by adding Micromet's human monoclonal antibody in Phase II trials to treat prostate and breast cancers and several early-phase antibody-based drugs.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment